*    Capital market activities undergoing fundamental relaunch
*    Investor communication take on prominent role in new company structure
*    Focus on notable increase of investor contacts

curasan AG (ISIN DE0005494538), a leading specialist for medical devices in the field of bone and tissue regeneration, today set the course for a fundamental relaunch of its capital markets activities. In the future Ingo Middelmenne will contribute his many years of experience and his international network to reposition curasan on the capital markets.

Following his university degree, Ingo Middelmenne started his career in the investment banking division of British bank HSBC, where he was active as Equity Research Analyst and later as Equity Sales Manager. After senior positions in Investor Relations for two index companies he founded Middelmenne & Cie. in 2007, a consultancy firm, based in Munich, specializing in Interim Management for capital market transactions and Investor Relations. Here he built and rebuilt IR departments for numerous small, mid and large cap companies and accompanied IPOs and bond placements in the amount of multiple billion Euros.

Michael Schlenk, the new CEO of curasan AG since late 2014, considers communication with investors a key task of curasan: 'With Mr. Middelmenne we could win an experienced Interim Manager, who as well has knowledge about companies, which have successfully performed a turnaround. He will support us on-site in shaping the strategic realignment and establishing a new foundation for our equity story.'

'This is a company with commercially viable products and numerous patents undergoing a disruptive change', Ingo Middelmenne describes the current situation of curasan. 'But the current valuation at start-up level shows that this story is still largely unknown in the market. This will be subject to change in the months to come as we will multiply the number of investor contacts.'

The company will announce further details on the strategy for the development of curasan AG over the next 24 months during the course of the forthcoming Annual General Meeting on June 25th, 2015.

Upcoming capital markets events of curasan AG:

24/04/2015 Roundtable Investor Meeting Munich CEO/IRO
04/05/2015 DVFA Small Cap Conference Frankfurt CEO/IRO
05/04/2015 DVFA Small Cap Conference Frankfurt CEO/IRO

About curasan AG:
curasan AG specialises in medical products for bone and tissue regeneration in the segment of regenerative medicine. It has set up a ground-breaking product pipeline of synthetic substitution and regeneration materials. Numerous patents and a comprehensive list of scientific documentation have established the clinical success of the products and the highly innovative strength of curasan AG. The list of users include surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons. The company is listed in the General Standard at the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8).

Contact:
Ingo Middelmenne
Head of Investor Relations
Tel. +49 6027 40900-45
Fax +49 6027 40900-39
ingo.middlemenne@curasan.de


Andrea Weidner
Head of Corporate Communications
Tel. +49 6027 40900-51
Fax +49 6027 40900-39
andrea.weidner@curasan.de
www.curasan.de